Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
Executive Summary
The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.
You may also be interested in...
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
The latest drug development news and highlights from our US FDA Performance Tracker.